BEAMBeam Therapeutics Inc.Mid cap · $3.19B · FY ending 2025-12-31
$31.00-5.14% · 2026-07-13 · EOD
22/100 composite
A transparent blend of the four reads below — each opens into the tool it comes from. Not advice.Quality17
margins & F-ScoreValue16
valuation vs its own rangeMomentum54
golden · price above 200-daySmart Money2
selling · 1 funds · 0P/10S insidersRevenue$139.7M
+120.0% y/y Mixed trendGolden crossAbove 200-day
vs S&P 500+2.1%
6-mo excess Trailing performance1M +5.1%
3M +13.0%
6M +10.7%
YTD +14.2%
1Y +40.7%
Piotroski F3/9
fundamental strength Altman ZSafe
bankruptcy zone ROIC = NOPAT ÷ (debt + equity − cash), using an effective tax rate of ~21%. Annual figures from SEC XBRL.
Net selling0P / 10S insiders · 1 funds hold · 0 Congress buys
Recent insidersSimon Amy · Chief Medical OfficerSELL$12,954
Evans John M. · CEOSELL$1.7M
FMR LLC · 10% ownerSELL$10.0M
Ciaramella Giuseppe · PresidentSELL$290,290
Fund holders (13F)ARK Investment Management (Cathie Wood)$289.1M2.2% of book
Bhealth · 72/100
Self-fundingSelf-funding — generates cash
- ●One-sided insider selling 10 insider sales and no open-market buys in the recent window.
Educational tools — not financial advice. Fundamentals from SEC EDGAR (XBRL); prices are end-of-day (Databento). Scores are a transparent blend of the components shown, computed on our own data — a research aid, not a recommendation.